Healthcare - Drug Manufacturers - General - NYSE - US
$ 24.8
-4.69 %
$ 141 B
Market Cap
33.07
P/E
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.[ Read More ]
The intrinsic value of one PFE stock under the base case scenario is HIDDEN Compared to the current market price of 24.8 USD, Pfizer Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart PFE
FINANCIALS
58.5 B
REVENUE
3.36 B
OPERATING INCOME
2.13 B
NET INCOME
8.7 B
OPERATING CASH FLOW
-32.3 B
INVESTING CASH FLOW
26.1 B
FINANCING CASH FLOW
17.7 B
REVENUE
5.28 B
OPERATING INCOME
4.5 B
NET INCOME
6.71 B
OPERATING CASH FLOW
-2.06 B
INVESTING CASH FLOW
-4.64 B
FINANCING CASH FLOW
Balance Sheet Decomposition
Pfizer Inc.
| Current Assets | 43.3 B |
| Cash & Short-Term Investments | 12.7 B |
| Receivables | 11.2 B |
| Other Current Assets | 19.5 B |
| Non-Current Assets | 183 B |
| Long-Term Investments | 15.4 B |
| PP&E | 21.9 B |
| Other Non-Current Assets | 146 B |
| Current Liabilities | 47.8 B |
| Accounts Payable | 6.71 B |
| Short-Term Debt | 7.57 B |
| Other Current Liabilities | 33.5 B |
| Non-Current Liabilities | 89.4 B |
| Long-Term Debt | 64.2 B |
| Other Non-Current Liabilities | 25.3 B |
EFFICIENCY
Earnings Waterfall
Pfizer Inc.
| Revenue | 58.5 B |
| Cost Of Revenue | 29.7 B |
| Gross Profit | 28.8 B |
| Operating Expenses | 25.4 B |
| Operating Income | 3.36 B |
| Other Expenses | 1.23 B |
| Net Income | 2.13 B |
RATIOS
49.25%
GROSS MARGIN
5.74%
OPERATING MARGIN
3.62%
NET MARGIN
2.38%
ROE
0.94%
ROA
4.27%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pfizer Inc.
| Net Income | 2.13 B |
| Depreciation & Amortization | 6.29 B |
| Capital Expenditures | -3.91 B |
| Stock-Based Compensation | 525 M |
| Change in Working Capital | -2.17 B |
| Others | -3.05 B |
| Free Cash Flow | 4.79 B |
Wall Street Analysts Price Targets
Pfizer Inc.
Wall Street analysts predict an average 1-year price target for PFE of $33.2 , with forecasts ranging from a low of $20 to a high of $45 .
PFE Lowest Price Target
Wall Street Target
20 USD
-19.35%
PFE Average Price Target
Wall Street Target
33.2 USD
34.07%
PFE Highest Price Target
Wall Street Target
45 USD
81.45%
4. DIVIDEND ANALYSIS
1.45%
DIVIDEND YIELD
0.42 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Pfizer Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
148 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
28.2 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
79.4 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 weeks ago
Oct 30, 2024
|
Bought 28.2 K USD
|
Gottlieb Scott
Director |
+ 1000
|
28.24 USD |
|
3 months ago
Aug 13, 2024
|
Sell 148 K USD
|
DAMICO JENNIFER B.
SVP & Controller |
- 5154
|
28.66 USD |
|
11 months ago
Dec 15, 2023
|
Bought 79.4 K USD
|
Gottlieb Scott
Director |
+ 3000
|
26.467 USD |
|
1 year ago
May 08, 2023
|
Bought 38.6 K USD
|
Gottlieb Scott
Director |
+ 1000
|
38.58 USD |
|
1 year ago
May 05, 2023
|
Bought 38.4 K USD
|
Gottlieb Scott
Director |
+ 1000
|
38.425 USD |
|
1 year ago
Mar 15, 2023
|
Sell 397 K USD
|
DAMICO JENNIFER B.
SVP & Controller |
- 9912
|
40.02 USD |
|
2 years ago
Jun 07, 2022
|
Sell 228 K USD
|
DAMICO JENNIFER B.
SVP & Controller |
- 4218
|
53.96 USD |
|
2 years ago
May 13, 2022
|
Sell 202 K USD
|
DAMICO JENNIFER B.
SVP & Controller |
- 4000
|
50.5 USD |
|
2 years ago
May 13, 2022
|
Sell 70.2 K USD
|
SAHNI PAYAL
Executive Vice President |
- 1408
|
49.84 USD |
|
2 years ago
May 12, 2022
|
Sell 1.65 M USD
|
Carapezzi William R JR
Executive Vice President |
- 32908
|
50 USD |
|
2 years ago
May 12, 2022
|
Sell 1.89 M USD
|
LANKLER DOUGLAS M
Executive Vice President |
- 38273
|
49.41 USD |
|
2 years ago
May 11, 2022
|
Sell 1.58 M USD
|
Dolsten Mikael
President R&D |
- 32015
|
49.31 USD |
7. News
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.
forbes.com
- 1 day ago
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Shares in some of America's largest drug manufacturers tumbled yesterday after President-elect Donald Trump announced Robert F. Kennedy Jr. as his pick for secretary of the Department of Health and Human Services (HHS).
fastcompany.com
- 1 day ago
Stock Of The Day: Is Pfizer Set Up To Rally?
Pfizer Inc. PFE shares are lower on Thursday due to news that President-elect Donald Trump picked Robert F. Kennedy Jr. as his next secretary of the Department of Health and Human Services.
benzinga.com
- 1 day ago
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.
investopedia.com
- 1 day ago
Pfizer (PFE) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
- 1 day ago
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
zacks.com
- 1 day ago
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.S. Department of Health and Human Services.
marketwatch.com
- 2 days ago
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and Innovation Officer, Executive Vice President, and Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:00 a.m. GMT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and.
businesswire.com
- 2 days ago
Pfizer Inc. (PFE) UBS Global Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) UBS Global Healthcare Conference November 13, 2024 3:30 PM ET Company Participants Aamir Malik - Chief Commercial Officer US Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're at the half hour.
seekingalpha.com
- 3 days ago
Buy These 5 Price-to-Book Value Stocks in November
The P/B ratio helps to identify low-priced stocks with high growth prospects. PFE, GM, GBX, ITRI and STNE are some such stocks.
zacks.com
- 3 days ago
Down -11.04% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)
Pfizer (PFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
- 3 days ago
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.
zacks.com
- 4 days ago
8. Profile Summary
Pfizer Inc. PFE
COUNTRY
US
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 141 B
Dividend Yield
1.45%
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Contact
235 East 42nd Street, New York, NY, 10017
https://www.pfizer.com
IPO Date
June 1, 1972
Employees
88000
Officers
Mr. Andreas J. Panayiotou
Global Chief Marketing Officer
Mr. Douglas M. Lankler
Executive Vice President & General Counsel
Mr. Rady A. Johnson
Executive Vice President and Chief Compliance, Quality & Risk Officer
Ms. Payal Sahni Becher
Chief People Experience Officer & Executive Vice President
Ms. Jennifer B. Damico
Senior Vice President, Controller & Principal Accounting Officer
Dr. Mikael Dolsten M.D., Ph.D.
Chief Scientific Officer and President of Research & Development
Ms. Francesca M. DeMartino
Chief Investor Relations Officer
Dr. Albert Bourla D.V.M., Ph.D.
Chairman of the Board & Chief Executive Officer
Ms. Lidia L. Fonseca
Executive Vice President and Chief Digital & Technology Officer
Mr. David M. Denton
Chief Financial Officer & Executive Vice President